New patent expiration for Galderma Labs drug SOOLANTRA
Drug Patent Watch
APRIL 21, 2024
Annual Drug Patent Expirations for SOOLANTRA Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers.
Sun.Apr 21, 2024
105 
“Heigh-ho” Taiho! The PTO Says LYTGOBI Patent is Ineligible for PTE Because of Untimely Application. And a Corrected NDA Approval Letter is No Saving Grace
FDA Law Blog: Biosimilars
APRIL 21, 2024
By Kurt R. Karst — If you’ve been following this blog since the early days, then you know we fervently followed the more-than-decade-long soap opera that was The Medicines Company’s efforts to obtain a Patent Term Extension (“PTE”) from the U.S. Patent and Trademark Office (“PTO”) for U.S. Patent No. 5,196,404 covering ANGIOMAX (bivalirudin) after the company’s patent counsel untimely filed for a PTE 62 days after the ANGIOMAX NDA 020873 approval at 5:18 PM on Friday, December 15, 2000 (see our
Join 42,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Agonist Treatment for Cannabis Use Disorder
Common Sense for Drug Policy Blog
APRIL 21, 2024
Agonist Treatment for Cannabis Use Disorder "Cannabinoid agonist treatment is unlikely to be an approach relevant to all cannabis users seeking treatment, as evidenced by the large numbers of individuals who did not complete the study screening process, and the modest 12-week treatment retention rates. Whereas nicotine-agonist and opioid-agonist treatments are considered front-line therapies, our findings suggest a more cautious approach for cannabinoid agonist treatment at this time.
New patent expiration for Endo Pharms drug MEGACE ES
Drug Patent Watch
APRIL 21, 2024
Annual Drug Patent Expirations for MEGACE+ES Megace Es is a drug marketed by Endo Pharms Inc and is included in one NDA.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Which pharmaceutical companies have the most syrup dosed drugs?
Drug Patent Watch
APRIL 21, 2024
This chart shows the pharmaceutical companies with the most syrup dosed drugs. For a different perspective, see the most popular dosage types.
Let's personalize your content